Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Part1: Advanced B-cell Malignancies × acalabrutinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Part1: Advanced B-cell Malignancies 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Prolymphocytic 1 Immunoproliferative Disorders 1 Immune System Diseases 1 COVID-19 1

Interventions

obinutuzumab 1 acalabrutinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03198650 2025-10-09

A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies

AstraZeneca

Phase 1 Active not recruiting

Part1: Advanced B-cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡